Navigation Links
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Date:2/2/2009

BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a conference call and webcast, with accompanying slide presentation, to discuss results from the CAPACITY program at 8:00 a.m. EST (5:00 a.m. PST) on Tuesday, February 3.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 84164912. To access the live webcast of the conference call, with accompanying slides, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 84164912.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio in
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... For millions of overweight Americans, regular exercise remains a ... type 2 diabetes. However, a new study suggests ... for others, depending on their genes. "While physical ... as effective for everyone when it comes to preventing ... Ruth Loos, director of the Genetics of Obesity and ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a leading ... market, announced the presentation of clinical data for Avance® ... of the Hand (ASSH) 2014 Annual Meeting which took ... The ASSH Best Paper Award was given to ”Functional ... Large Gap Nerve Discontinuities: Outcomes From a National Registry ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 During ... on natural approaches to health including achieving hormonal ... nutrient deficiencies and detoxification. , ... follows: , Date: October 6-9, 2014, Location: Online ... register: http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 ... private insurance exchanges within three years, profoundly impacting health ... pleased to announce its upcoming virtual conference, “Private ... offer a valuable lesson on where private health insurance ... the industry is expected to look like when they ...
Breaking Medicine News(10 mins):Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2
... to face depression, says a study that suggests that such ... substantial illness with significant morbidity for patients and their families ... the health portal WebMd. , ,Lee S. Cohen ... Boston women aged 36 to 45 for up to six ...
... study in the April edition Journal of the American ... boost the number of children// who select a calcium-rich ... the amount of saturated fat consumed from calcium-rich beverages. ... three ethnically diverse elementary schools in Florida. The results ...
... Children who drink juice do not face the risk of ... of the juice in children’s diet and body mass index ... this conclusion. // ,According to foodconsumer.org, he ... mass index for their age and that children aged 12-18 ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... people were being failed by the NHS says a joint ... Commission for Social Care Inspection. // Elder abuse is hurting ... people are subject to patronising and thoughtless attitudes from some ... place to another, their meals are whisked away uneaten for ...
... men who were born with an "incurable" genetic disorder ... infections has been repaired with Gene therapy. // Sixteen ... the once severely ill patients show signs of complete ... that this latest success will lead to further operations ...
Cached Medicine News:Health News:Neglect of the Elderly by the Community 2Health News:Gene Therapy Helps To Cure 'Incurable' Illness 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: